Nethaneel

Feinstein Institutes’ Chad Bouton receives Tesla Innovator of the Year Award

Retrieved on: 
Monday, November 20, 2023
Science, Research, Surgery, Health, Hospitals, Health Technology, Health Insurance, Clinical Trials, Medicine, Arm, Flowerfield Township, Michigan, Brain, Tetraplegia, Clinical trial, Learning, History, Wardenclyffe, Multimedia, College of Engineering (KNUST), Nethaneel, Algorithm, C4, Artificial intelligence, North Shore University Hospital, Movement, Northwell Health, System, Gala, Medical research, Paralysis, Credit, Wrist, Stony Brook University, Neurosurgery, Doctor of Philosophy, Sensation, Nikola Tesla Museum, C5, Forearm, Spinal cord, MD

Northwell Health and The Feinstein Institutes for Medical Research’s Chad Bouton received the Tesla Innovator of the Year Award from the Tesla Science Center at Wardenclyffe.

Key Points: 
  • Northwell Health and The Feinstein Institutes for Medical Research’s Chad Bouton received the Tesla Innovator of the Year Award from the Tesla Science Center at Wardenclyffe.
  • The award was given to him during the Annual Tesla Legacy Gala on November 16 at Flowerfields in St. James, NY.
  • View the full release here: https://www.businesswire.com/news/home/20231120274523/en/
    Chad Bouton (right) is handed the 2023 Tesla Innovator of the Year Award from Marc Alessi, executive director of the Tesla Science Center at Wardenclyffe during its Tesla Legacy Gala.
  • “It is a privilege to receive this award from the Tesla Science Center at Wardenclyffe.

Nuvei Promotes Yuval Ziv To President

Retrieved on: 
Thursday, February 17, 2022
SafeCharge, CEO, Risk, Company, Group, Nethaneel, Global Expansion Summit, Technology, Compliance, Retirement, Marketing, Growth, Simplex, Intelligence, TSX, GLOBE, Management, Bank, Nuvei

The appointments see Yuval Ziv, the Companys Managing Director, Digital Payments, promoted to President in a newly-created global role, Praful Morar, the Companys Chief Strategy Officer in Digital Payments, appointed Global Expansion Officer and Netanel Kabala appointed Chief Data and Analytics Officer.

Key Points: 
  • The appointments see Yuval Ziv, the Companys Managing Director, Digital Payments, promoted to President in a newly-created global role, Praful Morar, the Companys Chief Strategy Officer in Digital Payments, appointed Global Expansion Officer and Netanel Kabala appointed Chief Data and Analytics Officer.
  • In addition, Mark Pyke, President, North America, will retire at the end of March.
  • As President, Ziv will lead worldwide product, sales, marketing, client engagement and artificial intelligence-led capabilities.
  • He has been with the Nuvei group of companies for the past 15 years driving payments technology development across multiple industries.

StageOne Ventures Raises $235M and Launches Its Fourth Fund

Retrieved on: 
Tuesday, January 4, 2022
Nethaneel, IDF, TEL, Partner, Investment, Founder, B2B, Checkpoint, CFO, Venture capital, Cisco Systems, Nate, Technology, Partner (business rank), Time, VC, Financial services, Renewable energy, Video game

This new fund will continue investing in Israeli companies with a technological edge at the earliest stages, developing ground-breaking products for the enterprise market.

Key Points: 
  • This new fund will continue investing in Israeli companies with a technological edge at the earliest stages, developing ground-breaking products for the enterprise market.
  • Most of the investors in the new fund are repeat investors from previous StageOne funds, including institutional and private investors from the US, Israel, Europe and Japan.
  • StageOne has been active for two decades and has invested in over 50 companies to date, including some of Israel's most noted technology companies.
  • The fund focuses on early-stage ventures with innovative technologies that solve complex challenges for the enterprise and B2B markets.

StageOne Ventures Raises $235M and Launches Its Fourth Fund

Retrieved on: 
Tuesday, January 4, 2022
Nethaneel, IDF, TEL, Partner, Investment, Founder, B2B, Checkpoint, Fund, CFO, Venture capital, Cisco Systems, Technology, Partner (business rank), Time, VC, Financial services, Renewable energy, Video game, Nate

TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ -- Venture Capital firm StageOne Ventures has announced today it has completed raising $235 million towards its fourth fund, which will operate based on a dual model: a primary fund of $150 million to focus on seed investments for early-stage startups, and in parallel an additional $85 million will be used for follow-on investments in the new fund's leading portfolio companies. This brings StageOne's assets under management to $500M.

Key Points: 
  • This new fund will continue investing in Israeli companies with a technological edge at the earliest stages, developing ground-breaking products for the enterprise market.
  • Most of the investors in the new fund are repeat investors from previous StageOne funds, including institutional and private investors from the US, Israel, Europe and Japan.
  • StageOne is led by Yuval Cohen (Founder and Managing Partner), Tal Slobodkin (Managing Partner), Tal Jacobi (Partner and CFO) and Nate (Netanel) Meir, whose promotion to Partner coincided with the launch of the fourth fund.
  • The fund focuses on early-stage ventures with innovative technologies that solve complex challenges for the enterprise and B2B markets.

Oramed Pharmaceuticals Appoints Chief Legal Officer

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, Forward-looking statement, Company, Caspi, General counsel, Research, Knowledge, Biotechnology, Technology, Semiconductor Manufacturing International Corporation, Bar-Ilan University, Growth, Security (finance), Board of directors, Pressure, Method, Diabetes, POD, Board, TASE, Goldfarb, Norwegian Defence Security Department, Legislation, Nethaneel, Goldfarb Seligman & Co., Nasdaq, Management, Pharmaceutical industry

NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP)(TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, effective January 9, 2022.

Key Points: 
  • NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP)(TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, effective January 9, 2022.
  • "We are very pleased to welcome Netanel Derovan as Oramed's Chief Legal Officer.
  • Netanel's business-minded approach, legal acumenand strong operational skills will be instrumental to Oramed's ongoing progress and success and will further strengthen our executive team," stated Oramed Chief Executive Officer, Nadav Kidron.
  • Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.